SI-BONE, Inc. (NASDAQ: SIBN)

SI‑BONE develops minimally invasive treatments for sacroiliac joint dysfunction and related spinal conditions. The company designs and manufactures titanium implants and associated instruments that are used to stabilize bone and promote fusion. Founded in 2008 SI‑BONE pioneered the iFuse implant which delivers a minimally invasive option for sacroiliac joint fusion.

SI‑BONE generates revenue by selling its implants instruments and related disposables to hospitals ambulatory surgery centers and physicians. The company uses a direct sales force in the United States and a mix of direct representatives agents and resellers abroad. Revenue also comes from the sale of bone graft materials and from training and educational services provided to healthcare professionals.

SI‑BONE holds a leading position in the market for sacroiliac joint fusion and related spinal fixation products. The company differentiates itself through a strong base of clinical evidence including randomized controlled trials and long term follow up studies. Key competitors include Alphatec Holding Inc Aurora Spine Corporation Globus Medical Inc Medtronic plc and Tenon Medical Inc. The firm’s advantages stem from its dedicated sales team its breakthrough device designations and its reputation for procedural ease and safety.

SI‑BONE serves a broad base of health care providers primarily in the United States. As of December 31 2025 the company reported more than 12 000 U S physicians including approximately 7 500 orthopedic and neurological surgeons and about 4 500 interventional spine specialists. Internationally the company distributes its products through representatives and resellers in 38 countries. The customer base consists of hospitals ambulatory surgery centers and private practice physicians who perform spinal and pelvic procedures.